CapsoVision Announces Closing of Initial Public Offering
CapsoVision (NASDAQ: CV), a medical technology company specializing in capsule endoscopy solutions with advanced imaging and AI technologies, has successfully completed its Initial Public Offering (IPO). The company offered 5.5 million shares at $5.00 per share, raising gross proceeds of $27.5 million.
Trading commenced on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The underwriters, The Benchmark Company and Roth Capital Partners, have a 30-day option to purchase up to 825,000 additional shares at the IPO price, less underwriting discounts and commissions.
CapsoVision (NASDAQ: CV), un'azienda di tecnologia medica specializzata in soluzioni di endoscopia con capsula dotate di tecnologie avanzate di imaging e intelligenza artificiale, ha completato con successo la sua Offerta Pubblica Iniziale (IPO). La società ha offerto 5,5 milioni di azioni a 5,00 dollari per azione, raccogliendo un ricavo lordo di 27,5 milioni di dollari.
Le negoziazioni sono iniziate sul Nasdaq Capital Market il 2 luglio 2025, con il simbolo di borsa "CV". Gli underwriter, The Benchmark Company e Roth Capital Partners, hanno un'opzione di 30 giorni per acquistare fino a 825.000 azioni aggiuntive al prezzo IPO, al netto degli sconti e delle commissioni di sottoscrizione.
CapsoVision (NASDAQ: CV), una empresa de tecnología médica especializada en soluciones de endoscopia por cápsula con tecnologías avanzadas de imagen e inteligencia artificial, ha completado con éxito su Oferta Pública Inicial (OPI). La compañía ofreció 5,5 millones de acciones a 5,00 dólares por acción, recaudando ingresos brutos por 27,5 millones de dólares.
Las operaciones comenzaron en el Nasdaq Capital Market el 2 de julio de 2025, bajo el símbolo bursátil "CV". Los suscriptores, The Benchmark Company y Roth Capital Partners, tienen una opción de 30 días para comprar hasta 825,000 acciones adicionales al precio de la OPI, menos descuentos y comisiones de suscripción.
CapsoVision (NASDAQ: CV)은 첨단 영상 및 인공지능 기술을 활용한 캡슐 내시경 솔루션을 전문으로 하는 의료기술 회사로, 성공적으로 기업공개(IPO)를 완료했습니다. 회사는 550만 주를 주당 5.00달러에 제공하여 총 2750만 달러의 총수익을 확보했습니다.
거래는 2025년 7월 2일 나스닥 캐피털 마켓에서 "CV"라는 티커 심볼로 시작되었습니다. 인수주관사인 The Benchmark Company와 Roth Capital Partners는 IPO 가격에서 인수 수수료 및 할인액을 뺀 가격으로 최대 82만 5,000주를 추가로 구매할 수 있는 30일 옵션을 보유하고 있습니다.
CapsoVision (NASDAQ : CV), une entreprise de technologie médicale spécialisée dans les solutions d'endoscopie par capsule avec des technologies avancées d'imagerie et d'intelligence artificielle, a réussi son offre publique initiale (IPO). La société a proposé 5,5 millions d'actions au prix de 5,00 dollars par action, levant ainsi un produit brut de 27,5 millions de dollars.
La cotation a débuté sur le Nasdaq Capital Market le 2 juillet 2025, sous le symbole boursier « CV ». Les souscripteurs, The Benchmark Company et Roth Capital Partners, disposent d'une option de 30 jours pour acheter jusqu'à 825 000 actions supplémentaires au prix de l'IPO, moins les remises et commissions de souscription.
CapsoVision (NASDAQ: CV), ein Medizintechnologieunternehmen, das sich auf Kapselendoskopielösungen mit fortschrittlicher Bildgebung und KI-Technologien spezialisiert hat, hat erfolgreich seinen Börsengang (IPO) abgeschlossen. Das Unternehmen bot 5,5 Millionen Aktien zu je 5,00 US-Dollar an und erzielte damit Bruttoerlöse von 27,5 Millionen US-Dollar.
Der Handel begann am 2. Juli 2025 am Nasdaq Capital Market unter dem Börsensymbol „CV“. Die Konsortialführer, The Benchmark Company und Roth Capital Partners, haben eine 30-tägige Option, bis zu 825.000 zusätzliche Aktien zum IPO-Preis abzüglich Underwriting-Rabatten und Provisionen zu erwerben.
- Successfully raised $27.5 million in gross proceeds through IPO
- Achieved listing on Nasdaq Capital Market
- Underwriters have option to purchase additional 825,000 shares
- Company operates in growing medical technology sector with AI capabilities
- Relatively small IPO size at $27.5 million may limit growth potential
- Trading at the lower end of typical medical technology valuations at $5.00 per share
Insights
CapsoVision raises $27.5M in IPO at $5/share, providing capital for its medical imaging and AI capsule endoscopy business.
CapsoVision has successfully completed its initial public offering, raising
The
The joint book-running managers for this offering were The Benchmark Company and Roth Capital Partners. At the
Medical technology IPOs often face significant commercialization challenges, particularly for companies competing against established players in specialized fields like endoscopy. CapsoVision's success will likely depend on market adoption rates of its capsule endoscopy technology, reimbursement pathways, and the demonstrated clinical utility of its AI-enhanced imaging capabilities in real-world settings.
SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of
CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were
The Benchmark Company, LLC and Roth Capital Partners acted as joint book-running managers for the offering.
A registration statement on Form S-1 relating to the shares was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025. The offering was made only by means of a prospectus forming a part of such registration statement. Copies of the final prospectus may be obtained from The Benchmark Company, LLC, 150 East 58th Street, 17th Floor, New York, NY 10155, Attention: Prospectus Department, or by email at prospectus@benchmarkcompany.com
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Forward-Looking Statements
This press release contains or may contain forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expected”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions, and other risks described in the Company’s registration statement on Form S-1 filed with the SEC. Forward-looking statements speak only as of the date of this press release, and CapsoVision undertakes no obligation to update or revise these statements, except as required by law.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Kevin Lundquist
Chief Financial Officer, CapsoVision, Inc.
kml@capsovision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231
FAQ
How much did CapsoVision (CV) raise in its IPO?
When did CapsoVision (CV) stock begin trading on Nasdaq?
What is CapsoVision's (CV) main business focus?
Who were the underwriters for CapsoVision's (CV) IPO?
What is the additional share purchase option in CapsoVision's (CV) IPO?
